Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin

被引:95
作者
Reiter, RA
Knöbl, P
Varadi, K
Turecek, PL
机构
[1] Univ Vienna, Dept Med 1, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Clin Pharmacol, A-1090 Vienna, Austria
[3] Baxter Bio Sci, Vienna, Austria
关键词
D O I
10.1182/blood-2002-03-0814
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
von Willebrand factor-cleaving protease (ADAMTS13) cleaves von Willebrand factor (VWF) and regulates its physiologic function. To investigate the relation between ADAMTS13 activity and VWF, we compared ADAMTS13 activity with the VWF-related parameters VWF antigen (VWF:Ag), VWF collagen-binding activity (VWF:CBA), VWF-propeptide, proVWF, and VWF multimeric composition in 10 healthy volunteers and 3 patients with type 1 von Willebrand disease before and after infusing 0.3 mug/kg desmopressin. The VWF-related parameters in the volunteers increased 60 minutes after start of infusion by 3.7-fold for VWF:Ag, 7.2-fold for propeptide, and 2.2-fold for VWF: CBA. Unusually large VWF multimers and traces of proVWF appeared. The ADAMTS13 activity decreased to about half the initial value. After 24 hours values returned to baseline. Patients with type 1 von Wille-brand disease showed similar results. We conclude that the inverse correlation between ADAMTS13 and VWF-related parameters suggests a consumption of ADAMTS13 after the desmopressin-induced release of higher multimers of VWF. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:946 / 948
页数:3
相关论文
共 17 条
[1]   Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans [J].
Borchiellini, A ;
Fijnvandraat, K ;
tenCate, JW ;
Pajkrt, D ;
vanDeventer, SJH ;
Pasterkamp, G ;
MeijerHuizinga, F ;
ZwartHuinink, L ;
Voorberg, J ;
vanMourik, JA .
BLOOD, 1996, 88 (08) :2951-2958
[2]   von Willebrand factor: molecular size and functional activity [J].
Furlan, M .
ANNALS OF HEMATOLOGY, 1996, 72 (06) :341-348
[3]  
Gerritsen HE, 1999, THROMB HAEMOSTASIS, V82, P1386
[4]  
KNOBL P, 2002, ANN HEMATOL, V81, pA42
[5]   Changes in health and disease of the metalloprotease that cleaves von Willebrand factor [J].
Mannucci, PM ;
Canciani, MT ;
Forza, I ;
Lussana, F ;
Lattuada, A ;
Rossi, E .
BLOOD, 2001, 98 (09) :2730-2735
[6]   Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years [J].
Mannucci, PM .
BLOOD, 1997, 90 (07) :2515-2521
[7]   INVOLVEMENT OF LARGE PLASMA VONWILLEBRAND-FACTOR (VWF) MULTIMERS AND UNUSUALLY LARGE VWF FORMS DERIVED FROM ENDOTHELIAL-CELLS IN SHEAR-STRESS INDUCED PLATELET-AGGREGATION [J].
MOAKE, JL ;
TURNER, NA ;
STATHOPOULOS, NA ;
NOLASCO, LH ;
HELLUMS, JD .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (06) :1456-1461
[8]  
Oleksowicz L, 1999, CANCER RES, V59, P2244
[9]  
Sadler JE, 2000, THROMB HAEMOSTASIS, V84, P160
[10]   Biochemistry and genetics of von Willebrand factor [J].
Sadler, JE .
ANNUAL REVIEW OF BIOCHEMISTRY, 1998, 67 :395-424